Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
Boehringer Ingelheim

Generated: December 18, 2017

DrugPatentWatch Database Preview

ZANTAC 150 Drug Profile

« Back to Dashboard

When do Zantac 150 patents expire, and when can generic versions of Zantac 150 launch?

Zantac 150 is a drug marketed by Glaxosmithkline, Glaxo Grp Ltd, and Sanofi Us. and is included in four NDAs.

The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and forty suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
GlaxosmithklineZANTAC 150ranitidine hydrochlorideCAPSULE;ORAL020095-001Mar 8, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Glaxo Grp LtdZANTAC 150ranitidine hydrochlorideTABLET;ORAL018703-001Jun 9, 1983ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxo Grp LtdZANTAC 150ranitidine hydrochlorideGRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxo Grp LtdZANTAC 150ranitidine hydrochlorideTABLET, EFFERVESCENT;ORAL020251-001Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi UsZANTAC 150ranitidine hydrochlorideTABLET;ORAL021698-002Mar 13, 2007OTCYesNo► Subscribe► Subscribe► Subscribe
Sanofi UsZANTAC 150ranitidine hydrochlorideTABLET;ORAL021698-001Aug 31, 2004OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ZANTAC 150

Drugname Dosage Strength RLD Submissiondate
ranitidine hydrochlorideTablets150 mgZantac 15010/30/2007

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: